Rheumatology Advance Access originally published online on November 5, 2008
Rheumatology 2009 48(1):88-89; doi:10.1093/rheumatology/ken413
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Resolution of Behcet's disease after non-myeloablative allogeneic stem cell transplant for acute myeloid leukaemia
1Blood and Marrow Transplant Program, Cancer Center of the High Plains, Texas Oncology, 2Oncology Unit, Northwest Texas Hospital Healthcare System and 3Rheumatology Section, Amarillo Diagnostic Clinic, Amarillo, TX, USA
Correspondence to: S. H. Lim, Cancer Center of the High Plains, Texas Oncology, 1000 Coulter Drive, Amarillo, TX 79106, USA. E-mail: seah.lim@usoncology.com
| The first 10% of the full text of this article appears below. |
SIR, Behcet's disease (BD) commonly affects younger patients. The diagnosis is generally made from a cluster of symptomatologies, including recurrent orogenital ulcers, skin rash, seronegative arthritis and uveitis. The diagnosis requires the presence of recurrent oral ulceration with two of four minor criteria that include anterior uveitis and papulopustular skin lesions. Although usually an indolent course, BD can result in life-threatening complications such as meningitis, stroke, pulmonary haemorrhage and thromboembolic disease. Anti-inflammatory drugs and immunosuppressive agents are the main therapeutics; in